Ketamine: new indications for an old drug.

Curr Drug Targets

Institute of Anaesthesia and Intensive Care, Catholic University of the Sacred Heart, Rome, Italy.

Published: November 2005

Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960's but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990's, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945005774574533DOI Listing

Publication Analysis

Top Keywords

ketamine
5
ketamine indications
4
indications drug
4
drug ketamine
4
ketamine non-competitive
4
non-competitive antagonist
4
antagonist phencyclidine
4
phencyclidine site
4
site n-methyl-d-aspartate
4
n-methyl-d-aspartate nmda
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!